Sonoma's CEO handoff Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 21 November, 2025

The hematology sector heads into ASH under pressure, with data that could reshape R&D strategies and investment decisions across blood disorders. Join our expert analysis of the year’s most consequential readouts. Sign up today.

presented by Where ded­i­ca­tion de­liv­ers ex­cel­lence in bi­o­log­ics

news GSK, AnaptysBio enter legal battle over decade-old Jemperli licensing deal Peer Review Jeff Bluestone, Stephen Dilly talk CEO handoff, what’s next for Sonoma; Scott Gottlieb's next move In RFK’s first respiratory season as HHS chief, vaccine use slides while health officials elevate suspicion Post-Hoc Live: The drug industry’s Mr. Reality Check, Derek Lowe

Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine

Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium coworking and meeting space just steps from the action. Save $200 with Early Bird rates — reserve your spot today.

endpoints pharma FDA will allow email 'clarifications' after pharma company meetings AbbVie, Novartis can proceed with legal fight against Utah 340B law Novartis, Moderna detail manufacturing expansions in the US, among others Pentagon-backed Lumen is ready to drastically slash antibody manufacturing costs

in case you missed it 1. Dispatches from Jefferies: Why Alkermes wants Avadel, Light Chain’s hope for CD47, and more 2. Flagship and portfolio companies do deals with GSK, Merck KGaA and Saudi Arabia 3. FDA approves new indication and monthly dose of Regeneron’s Eylea HD 4. Aspen gets $115M for Parkinson's cell therapy, potential IPO in sight next year 5. After Phase 3 hit, Innovent to seek China approval of high-dose obesity shot it got from Lilly 6. Novartis raises the sales bar for key cancer drugs, tweaks yearly growth guidance 7. News Briefing Abbott's $21B diagnostic deal; Job cuts at Applied Therapeutics and AbbVie 8. CDC in turmoil after agency backpedals on rejecting vaccines-autism link